Clinical Trial

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Study acronym: Illuminate1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 26 locations 2026-05-12
Trial Details
NCT Number NCT07494305
Lead Sponsor LB Pharmaceuticals Inc.
Conditions Bipolar I Disorder
Enrollment 320 participants
Start Date 2026-01-23
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-27